{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:56:18Z","timestamp":1791280578746,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"DOI":"10.1007\/s40801-026-00586-2","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:41:55Z","timestamp":1791279715000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PCSK9 inhibitors usage in South China: A Multi-Center Real-World Study"],"prefix":"10.1007","author":[{"given":"Qiuyan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengmei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmundo Patricio Lopes","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Io Chon","family":"Vong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam In","family":"Ung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaorong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Edgar","family":"Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn Choon Beng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Tak Wai","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai Hang","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian Chi Kei","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine Sze Ling","family":"Chui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"issue":"10204","key":"586_CR1","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","volume":"394","author":"M Zhou","year":"1990","unstructured":"Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 1990;394(10204):1145\u201358. https:\/\/doi.org\/10.1016\/S0140-6736(19)30427-1.","journal-title":"Lancet"},{"issue":"11","key":"586_CR2","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/eurjpc\/zwae281","volume":"32","author":"B Chong","year":"2025","unstructured":"Chong B, Jayabaskaran J, Jauhari SM, et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur J Prev Cardiol. 2025;32(11):1001\u201315. https:\/\/doi.org\/10.1093\/eurjpc\/zwae281.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"586_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pop.2012.11.003","volume":"40","author":"RH Nelson","year":"2013","unstructured":"Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013;40(1):195\u2013211. https:\/\/doi.org\/10.1016\/j.pop.2012.11.003.","journal-title":"Prim Care"},{"issue":"1","key":"586_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-023-03348-y","volume":"23","author":"B Addisu","year":"2023","unstructured":"Addisu B, Bekele S, Wube TB, Hirigo AT, Cheneke W. Dyslipidemia and its associated factors among adult cardiac patients at Ambo university referral hospital, Oromia region, west Ethiopia. BMC Cardiovasc Disord. 2023;23(1):321. https:\/\/doi.org\/10.1186\/s12872-023-03348-y.","journal-title":"BMC Cardiovasc Disord"},{"key":"586_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062444","author":"G Bosco","year":"2023","unstructured":"Bosco G, Di Giacomo Barbagallo F, Spampinato S, et al. Management of statin intolerant patients in the era of novel lipid lowering therapies: a critical approach in clinical practice. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12062444.","journal-title":"J Clin Med"},{"issue":"17","key":"586_CR6","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1093\/eurheartj\/ehr080","volume":"32","author":"JR Banegas","year":"2011","unstructured":"Banegas JR, L\u00f3pez-Garc\u00eda E, Dallongeville J, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011;32(17):2143\u201352. https:\/\/doi.org\/10.1093\/eurheartj\/ehr080.","journal-title":"Eur Heart J"},{"issue":"2","key":"586_CR7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1185\/03007990903500565","volume":"26","author":"MP Hermans","year":"2010","unstructured":"Hermans MP, Castro Cabezas M, Strandberg T, et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin. 2010;26(2):445\u201354. https:\/\/doi.org\/10.1185\/03007990903500565.","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"586_CR8","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jacc.2009.10.042","volume":"55","author":"HJ Avis","year":"2010","unstructured":"Avis HJ, Hutten BA, Gagn\u00e9 C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol. 2010;55(11):1121\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2009.10.042.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"586_CR9","doi-asserted-by":"publisher","DOI":"10.21542\/gcsp.2017.2","volume":"2017","author":"NG Seidah","year":"2017","unstructured":"Seidah NG. The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol. Glob Cardiol Sci Pract. 2017;2017(1):e201702. https:\/\/doi.org\/10.21542\/gcsp.2017.2.","journal-title":"Glob Cardiol Sci Pract"},{"issue":"2","key":"586_CR10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rab\u00e8s JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154\u20136. https:\/\/doi.org\/10.1038\/ng1161.","journal-title":"Nat Genet"},{"key":"586_CR11","doi-asserted-by":"publisher","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task\u00a0Force\u00a0on\u00a0Clinical Practice Guidelines. J Am College Cardiol. 2019;73(24):3168\u2013209. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.002(Epub 2018 Nov 10. Erratum in: J Am Coll Cardiol. 2019 Jun 25;73(24):3234-3237. 10.1016\/j.jacc.2019.05.012. PMID: 30423391).","DOI":"10.1016\/j.jacc.2018.11.002"},{"key":"586_CR12","doi-asserted-by":"publisher","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455(Erratum in: Eur Heart J. 2020 Nov 21;41(44):4255. 10.1093\/eurheartj\/ehz826. PMID: 31504418).","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"586_CR13","unstructured":"Summary of national guidance for lipid management. NHS. https:\/\/www.england.nhs.uk\/aac\/wp-content\/uploads\/sites\/50\/2020\/04\/lipid-management-pathway-v7.pdf."},{"issue":"22","key":"586_CR14","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"18","key":"586_CR15","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"issue":"9","key":"586_CR16","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s40618-019-01019-4","volume":"42","author":"I Dicembrini","year":"2019","unstructured":"Dicembrini I, Giannini S, Ragghianti B, Mannucci E, Monami M. Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Endocrinol Investig. 2019;42(9):1029\u201339. https:\/\/doi.org\/10.1007\/s40618-019-01019-4.","journal-title":"J Endocrinol Investig"},{"key":"586_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0358-8","volume":"13","author":"XL Zhang","year":"2015","unstructured":"Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123. https:\/\/doi.org\/10.1186\/s12916-015-0358-8.","journal-title":"BMC Med"},{"issue":"15","key":"586_CR18","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/heartjnl-2019-314763","volume":"105","author":"H Du","year":"2019","unstructured":"Du H, Li X, Su N, et al. Proprotein convertase subtilisin\/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis. Heart. 2019;105(15):1149\u201359. https:\/\/doi.org\/10.1136\/heartjnl-2019-314763.","journal-title":"Heart"},{"key":"586_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10173828","author":"A Smith","year":"2021","unstructured":"Smith A, Johnson D, Banks J, Keith SW, Karalis DG. Trends in PCSK9 inhibitor prescriptions before and after the price reduction in patients with atherosclerotic cardiovascular disease. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10173828.","journal-title":"J Clin Med"},{"issue":"1","key":"586_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-024-02208-1","volume":"23","author":"L Zhang","year":"2024","unstructured":"Zhang L, Wang X, Yao H, Ding B, Gao X, Li X. Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis. Int J Equity Health. 2024;23(1):116. https:\/\/doi.org\/10.1186\/s12939-024-02208-1.","journal-title":"Int J Equity Health"},{"key":"586_CR21","unstructured":"National Healthcare Security Administration. Notice on the issuance of the national drug list for basic medical insurance, work injury insurance and maternity insurance. 2021. https:\/\/www.nhsa.gov.cn\/art\/2021\/12\/3\/art_37_7429.html."},{"issue":"1","key":"586_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2023.2218633","volume":"11","author":"B Macabeo","year":"2023","unstructured":"Macabeo B, Wilson L, Xuan J, et al. Access to innovative drugs and the National Reimbursement Drug List in China: changing dynamics and future trends in pricing and reimbursement. J Mark Access Health Policy. 2023;11(1):2218633. https:\/\/doi.org\/10.1080\/20016689.2023.2218633.","journal-title":"J Mark Access Health Policy"},{"key":"586_CR23","doi-asserted-by":"publisher","first-page":"1190934","DOI":"10.3389\/fphar.2023.1190934","volume":"14","author":"JJ Li","year":"2023","unstructured":"Li JJ, Zhao SP, Zhao D, et al. 2023 Chinese guideline for lipid management. Front Pharmacol. 2023;14:1190934. https:\/\/doi.org\/10.3389\/fphar.2023.1190934. (PMID: 37711173; PMCID: PMC10498001).","journal-title":"Front Pharmacol"},{"key":"586_CR24","unstructured":"National Healthcare Security Administration, National Health Commission. Notice on adapting to the regularization of national medical insurance negotiations and sustaining the implementation of negotiated drugs. 2021. https:\/\/www.gov.cn\/zhengce\/zhengceku\/2021-09\/11\/content_5636762.htm. Accessed 30 Jan 2026."},{"key":"586_CR25","unstructured":"Hospital Authority. HA Drug Formulary. 2026. https:\/\/www.ha.org.hk\/hadf\/en\/Others\/Search-Result.html?#gsc.tab=0. Accessed 30 Jan 2026."},{"key":"586_CR26","unstructured":"Hospital Authority. HA Drug Formulary. Frequently Asked Questions. What are Special drugs? 2026. https:\/\/www.ha.org.hk\/hadf\/en\/Resources\/Faq.html#gsc.tab=0. Accessed 30 Jan 2026."},{"key":"586_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwag122","author":"B Zhu","year":"2026","unstructured":"Zhu B, Liao Y, Yu Q, et al. Real-world evidence on prescribing patterns and lipid-lowering effectiveness of monoclonal antibody PCSK9 inhibitors from Hong Kong. Eur J Prev Cardiol. 2026. https:\/\/doi.org\/10.1093\/eurjpc\/zwag122.","journal-title":"Eur J Prev Cardiol"},{"key":"586_CR28","unstructured":"Macau Health Bureau. Healthcare coverage, healthcare benefits, free healthcare. https:\/\/ssm.gov.mo\/portal\/content\/ch\/1751\/fulldetail.aspx. Accessed 30 Jan 2026."},{"key":"586_CR29","unstructured":"Greater Bay Area. Overview. https:\/\/www.bayarea.gov.hk\/en\/about\/overview.html. Accessed 17 Mar 2026."},{"key":"586_CR30","unstructured":"Overview of the Health Care System in Hong Kong. https:\/\/www.gov.hk\/en\/residents\/health\/hosp\/overview.htm. Accessed 30 Jan 2026."},{"key":"586_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h6926","volume":"352","author":"AYS Wong","year":"2016","unstructured":"Wong AYS, Root A, Douglas IJ, et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. BMJ. 2016;352:h6926. https:\/\/doi.org\/10.1136\/bmj.h6926.","journal-title":"BMJ"},{"issue":"3","key":"586_CR32","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/ehjdh\/ztae018","volume":"5","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Lin CJ, Yu Q, et al. Development and validation of risk prediction model for recurrent cardiovascular events among Chinese: the Personalized CARdiovascular DIsease risk Assessment for Chinese model. Eur Heart J Digit Health. 2024;5(3):363\u201370. https:\/\/doi.org\/10.1093\/ehjdh\/ztae018.","journal-title":"Eur Heart J Digit Health"},{"issue":"1","key":"586_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s44325-024-00011-z","volume":"1","author":"Q Yu","year":"2024","unstructured":"Yu Q, Fan M, Lin CJ, et al. Risk factors for long-term cardiovascular post-acute sequelae of COVID-19 infection: a nested case-control study in Hong Kong. npj Cardiovasc Health. 2024;1(1):10. https:\/\/doi.org\/10.1038\/s44325-024-00011-z.","journal-title":"npj Cardiovasc Health"},{"key":"586_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101504","volume":"50","author":"CSL Chui","year":"2022","unstructured":"Chui CSL, Fan M, Wan EYF, et al. Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: a self-controlled case series study. EClinicalMedicine. 2022;50:101504. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101504.","journal-title":"EClinicalMedicine"},{"key":"586_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2021.05.016","volume":"328","author":"JE Blais","year":"2021","unstructured":"Blais JE, Wei Y, Yap KKW, et al. Trends in lipid-modifying agent use in 83 countries. Atherosclerosis. 2021;328:44\u201351. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.05.016.","journal-title":"Atherosclerosis"},{"key":"586_CR36","unstructured":"The University of Hong Kong-Shenzhen Hospital. Available from: https:\/\/www.hku-szh.org\/en\/. [Accessed 30 Jan 2026]."},{"key":"586_CR37","unstructured":"Optimising the service model for Macao\u2019s new outlying island hospital. Available from: https:\/\/ssm.gov.mo\/docs\/20159\/20159_23f4f179b0dc492f8444a10ae3177dd5_000.pdf. [Accessed 30 Jan 2026]."},{"key":"586_CR38","unstructured":"Overview of University Hospital. Available from: https:\/\/www.uh.org.mo\/en\/about\/intro. [Accessed 30 Jan 2026]."},{"key":"586_CR39","unstructured":"The First Affiliated Hospital of Jinan University\u2014Regional. First Affiliated Hospital becomes a national model center. . https:\/\/english.jnu.edu.cn\/2019\/0225\/c2027a272385\/page.psp. Accessed 30 Jan 2026."},{"issue":"1","key":"586_CR40","doi-asserted-by":"publisher","DOI":"10.2174\/011573403X357542250526072430","volume":"22","author":"AS Cleto","year":"2026","unstructured":"Cleto AS, Schirlo JM, Machozeki J, Martins CM. Alirocumab versus evolocumab on cardiovascular outcomes: a systematic review and meta-analysis. Curr Cardiol Rev. 2026;22(1):e1573403X1357542. https:\/\/doi.org\/10.2174\/011573403X357542250526072430.","journal-title":"Curr Cardiol Rev"},{"key":"586_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1283922","volume":"15","author":"W Zhou","year":"2024","unstructured":"Zhou W, Liang Z, Lou X, et al. The combination use of inclisiran and statins versus statins alone in the treatment of dyslipidemia in mainland China: a cost-effectiveness analysis. Front Pharmacol. 2024;15:1283922. https:\/\/doi.org\/10.3389\/fphar.2024.1283922.","journal-title":"Front Pharmacol"},{"issue":"5","key":"586_CR42","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jacl.2022.06.009","volume":"16","author":"D Soffer","year":"2022","unstructured":"Soffer D, Stoekenbroek R, Plakogiannis R. Small interfering ribonucleic acid for cholesterol lowering\u2014inclisiran: inclisiran for cholesterol lowering. J Clin Lipidol. 2022;16(5):574\u201382. https:\/\/doi.org\/10.1016\/j.jacl.2022.06.009. (Epub 2022 Jun 28. PMID: 35909047).","journal-title":"J Clin Lipidol"},{"issue":"3","key":"586_CR43","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40265-025-02146-4","volume":"85","author":"HA Blair","year":"2025","unstructured":"Blair HA. Ebronucimab: first approval. Drugs. 2025;85(3):437\u201341. https:\/\/doi.org\/10.1007\/s40265-025-02146-4.","journal-title":"Drugs"},{"issue":"11","key":"586_CR44","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.033669","volume":"13","author":"X Wang","year":"2024","unstructured":"Wang X, Qiu M, Cheng Z, et al. Efficacy and safety of ongericimab in Chinese patients with primary hypercholesterolemia and mixed dyslipidemia. J Am Heart Assoc. 2024;13(11):e033669. https:\/\/doi.org\/10.1161\/JAHA.123.033669.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"586_CR45","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1001\/jama.2025.20620","volume":"335","author":"CM Ballantyne","year":"2026","unstructured":"Ballantyne CM, Gellis L, Tardif J-C, et al. Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial. JAMA. 2026;335(2):129\u201339. https:\/\/doi.org\/10.1001\/jama.2025.20620.","journal-title":"JAMA"},{"key":"586_CR46","unstructured":"Health Bureau. The healthcare challenges in Hong Kong. Available from: https:\/\/www.primaryhealthcare.gov.hk\/bp\/en\/supplementary-documents\/challenges\/. [Accessed 30 Jan 2026]."},{"key":"586_CR47","unstructured":"Hospital Authority. Hospital authority drug formulary management. Available from: https:\/\/www.ha.org.hk\/hadf\/en-us\/Updated-HA-Drug-Formulary\/Drug-Formulary.html. [Accessed 30 Jan 2026]."},{"key":"586_CR48","doi-asserted-by":"publisher","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias: developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2025;46(42):4359\u201378. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190(Erratum in: Eur Heart J. 2026 Feb 11;47(6):697. PMID: 40878289).","DOI":"10.1093\/eurheartj\/ehaf190"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00586-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00586-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00586-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:41:58Z","timestamp":1791279718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00586-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":48,"alternative-id":["586"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00586-2","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"15 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Olivia Monteiro received research funding from the Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia (FDCT) in Macau. Kathryn Choon Beng Tan has received advisory board fees from Daiichi Sankyo and Eli Lilly; and speaker fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk, and Sanofi. David Tak Wai Lui received lecture\/consultation fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GSK, and Sanofi; advisory board from Daiichi Sankyo; and a grant from iNova Pharmaceuticals. Ian Chi Kei Wong reports grants from Amgen, Bristol-Myers Squibb, Pfizer, Janssen, Bayer, GSK, Novartis, Hong Kong RGC, Hong Kong Health and Medical Research Fund in Hong Kong, National Institute for Health Research in England, European Commission, and National Health and Medical Research Council in Australia, consulting fees from IQVIA, payment for expert testimony, and is an independent non-executive director of Advanced Data Analytic for Medical Science (ADAMS) Limited, Jacobson Medical in Hong Kong, outside of the submitted work; there are no other relationships or activities that could appear to have influenced the submitted work. Celine Sze Ling Chui reports grants from the Food and Health Bureau of the Hong Kong Government, Hong Kong Research Grant Council, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, MSD, and Amgen and personal fees from MSD and PrimeVigilance, and is the CEO of Advanced Data Analytic for Medical Science (ADAMS) Limited, outside the submitted work; there are no other relationships or activities that could appear to have influenced the submitted work. Joseph Edgar Blais is an Editorial Board member of\n                      Drugs - Real World Outcomes\n                      . Joseph Edgar Blais was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Joseph Edgar Blais reports research grants from the Research Fund Secretariat of the Food and Health Bureau (Health and Medical Research Fund [HMRF], Hong Kong SAR) outside the submitted work. All other co-authors have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional review boards of all participating centers. Ethics approval was obtained from the Institutional Review Board of the HKU\/HA HKW for HKHA (UW 22-679), the Medical Ethics Committee of HKU-SZH ([2022]168), the Ethical Committee of Centro Hospitalar Conde de S\u00e3o Janu\u00e1rio, Macau Health Bureau for SSM (0021\/MEC\/N\/2024), the UH Clinical Research Ethics Committee for MUST-UH (UH\/CREC\/2024\/04), and the Ethics Committee of the JNUH (KY-2024-099).","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Because of the retrospective nature of the study using de-identified EHR data, a waiver of informed consent was granted by the respective committees at each center.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data underlying this article are not available and cannot be shared publicly as stipulated in the Institutional Review Board application protocol.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Concept and design: QY, TTM, ICKW, CSLC; acquisition, analysis, or interpretation of data:\u00a0QY, TTM, FH, OM, EPLL, ICV, SIU, SL, SW, JW, JEB, KCBT, DTWL, KHY, ICKW, CSLC; drafting of the manuscript: QY; critical review of the manuscript for important intellectual content:\u00a0QY, TTM, FH, OM, EPLL, ICV, SIU, SL, SW, JW, JEB, KCBT, DTWL, KHY, ICKW, CSLC; statistical analysis:\u00a0QY, TTM; administrative, technical, or material support:\u00a0QY, TTM, ICKW, CSLC; supervision: ICKW, CSLC. All authors read and approved the final version.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}